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ABSTRACT
Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with
activity against graft-versus-host disease (GVHD). In a phase II trial assessing the GVHD prophylactic effects
of HCQ, 51 consecutive unrelated donor transplant recipients received HCQ in addition to cyclosporin A,
methylprednisolone, and methotrexate. HCQ was initiated on pretransplantation day 21 at 800 mg/d and
continued until day 100 after transplantation. HCQ was extremely well tolerated and was not associated with
side effects. Pharmacokinetic analyses demonstrated large inter- and intrapatient variability. The addition of
HCQ did not affect posttransplantation immune recovery. Grade II to IV acute GVHD was observed in 56%
of patients, and grade III and IV GVHD was observed in 17%. Day 100 mortality was 22%. When compared
with a matched cohort of patients reported to the International Bone Marrow Transplant Registry, patients
receiving HCQ had comparable cumulative incidences of grade II to IV acute GVHD. However, lower
incidences of grades III and IV GVHD and better GVHD-free survival were observed in HCQ-treated patients
(P  .01). We conclude that prophylactic HCQ is well tolerated and associated with a low incidence of severe
acute GVHD. An ongoing placebo-controlled randomized trial will further determine what role HCQ plays in
preventing GVHD after allografting.
© 2003 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Unrelated donor (URD) hematopoietic stem cell
ransplantation is a curative treatment for a variety of
ematologic disorders [1]; however, and despite mod-
rn pharmacologic immunosuppressive prophylaxis,
cute graft-versus-host disease (GVHD) remains a
igniﬁcant limiting factor to the success of transplan-
ation [2-4]. Hydroxychloroquine (HCQ) is a lysoso-
otropic amine that interferes with antigen process-
ng and presentation [5-7]. HCQ also reduces T-cell
roliferation in response to multiple stimuli, including e
14llogeneic minor histocompatibility antigens [6,7].
CQ acts synergistically with the immunosuppressive
ctivity of cyclosporin A (CSA) and has anti-GVHD
ctivity in various murine allogeneic transplant models
7-9]. Initiation of HCQ before the marrow infusion
nd its continuation after transplantation resulted in
ear-complete elimination of acute GVHD and in a
arked survival advantage in HCQ-treated murine
ecipients of minor histocompatibility antigen–mis-
atched transplants [10]. Gilman et al. [11] reportedprophylaxis
oi:10.1016/j.bbmt.2003.08.006ncouraging response rates with HCQ in 40 patients
with steroid-resistant or steroid-dependent chronic
GVHD.
On the basis of the preclinical and clinical anti-
GVHD activity of HCQ, we sought to determine the
prophylactic effects of HCQ on acute GVHD in re-
cipients of URD transplantation. The outcomes of
study patients were compared with those of a matched
cohort of patients reported to the International Bone
Marrow Transplant Registry (IBMTR).
MATERIALS AND METHODS
Patients
Between October 1997 and July 1999, 51 consec-
utive patients with hematologic malignancies and who
were undergoing URD bone marrow transplantation
were enrolled in the study and are included in this
analysis. The Institutional Review Board of Washing-
ton University School of Medicine approved the
study, and all patients gave written, informed consent.
Donors
Donors were identiﬁed and selected through the
National Marrow Donor Program. HLA matching
was performed by serologic methods for HLA A and
B antigens. Class II HLA antigens were typed by
using high-resolution sequence-speciﬁc oligonucleo-
tide probes for HLA-DRB1 alleles.
Conditioning Regimen and Transplantation
Conditioning included cyclophosphamide (60 mg/
kg/d IV on days 2 and 1) and low-dose (550 cGy)
total body irradiation (TBI) delivered as a single dose
at a high dose rate (30 cGy/min 15%) on day 0. The
irradiation was delivered in parallel and opposed lat-
eral ﬁelds with a 6-MV photon linear accelerator (Cli-
nac 600 CD; Varian Medical Systems, Alpharetta,
GA), as previously described [12,13]. Within 8 hours
of the TBI, unmanipulated donor marrow was infused
intravenously though a pheresis catheter. The day of
the marrow infusion was designated day 0.
GVHD Prophylaxis
All patients received CSA, methotrexate (MTX),
methylprednisolone (MP), and HCQ for GVHD pro-
phylaxis. HCQ was administered orally at 800 mg/d in
2 equally divided doses starting 21 days before trans-
plantation. HCQ was discontinued on day 100 after
transplantation. CSA was prescribed at 3 mg/kg/d as a
continuous intravenous infusion, starting on day 1
and continuing until day 100 after transplantation.
CSA was subsequently changed to an oral formulation
(5 mg/kg twice daily) on day100 and was tapered off
by day 180 in the absence of GVHD. MTX was
administered at 10 mg/m2 intravenously on day 1
and at 7.5 mg/m2 on day 3 and day 6. MP was
started at 1 mg/kg intravenously on day 7, changed
to equivalent doses of oral prednisone on discharge
from the hospital, and tapered off between day 28
and day 56 in the absence of acute GVHD.
Safety Assessment
The toxicity of HCQ was monitored with visual
acuity and funduscopic examination performed before
the initiation of HCQ, on a monthly basis until day
100, and yearly thereafter. Recipients with a history
of retinitis or in whom a complete funduscopic exam-
ination was not possible were excluded from the study.
Supportive Care
All patients received prophylactic antibacterial
medication until neutrophil engraftment according to
the Washington University institutional policies. Tri-
methoprim/sulfamethoxazole was administered for
Pneumocystis carinii prophylaxis on engraftment, itra-
conazole was administered for fungal prophylaxis, and
acyclovir was administered for prevention of herpes
simplex virus reactivation. All patients were nursed in
laminar airﬂow rooms equipped with high-efﬁcacy
particulate air ﬁlters for protective isolation. Granu-
locyte colony-stimulating factor (Neupogen; Amgen,
Thousand Oaks, CA) 10 g/kg/d subcutaneously was
started on posttransplantation day7 and was discon-
tinued on neutrophil engraftment. Serum immuno-
globulin G levels were obtained monthly during the
ﬁrst year after transplantation, and intravenous immu-
noglobulin was administered when serum immuno-
globulin G was 400 mg/dL.
Engraftment and Chimerism Analyses
Neutrophil engraftment was deﬁned as the ﬁrst of
3 consecutive days in which the absolute neutrophil
counts exceeded 500/L. Platelet engraftment was
deﬁned as the ﬁrst of 7 consecutive days in which the
platelet counts were 20 000/L without platelet
transfusions. Lymphoid hematopoietic chimerism was
assessed on day 30, 100, 180, and 365 and
yearly thereafter by using variable number of tandem
repeats, as previously described [14].
Diagnosis, Staging, and Treatment of Acute
GVHD
Acute GVHD was diagnosed clinically before day
100 and was conﬁrmed histologically. Acute GVHD
was staged and graded according to standard criteria
[15]. Initial treatment of acute GVHD consisted of
escalating the dose of MP to 2 mg/kg/d. Patients who
did not respond to MP as primary therapy were
treated with either antithymocyte globulin, as previ-
ously described [16], or investigational agents.
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Pharmacokinetic Assays
Blood samples were obtained before initiation of
the ﬁrst HCQ dose and weekly thereafter until cessa-
tion of HCQ (day100). Samples were centrifuged to
yield plasma and cryopreserved in liquid nitrogen un-
til analysis. Plasma (0.5 mL) with an internal standard
(chloroquine 1 g) was combined with 100 L of 2 M
sodium hydroxide for deionization and vortexed, and
5 mL of diethyl ether was added to extract HCQ
[17,18]. The extracted supernatant was obtained by
centrifugation and combined with 0.3 mL of 0.01 M
hydrochloric acid, vortexed, and centrifuged to yield
the aqueous phase [18]. A ﬁnal volume of 50 L from
the aqueous phase was injected onto a column (Supel-
cosil LC-ABZ column [4.6  150 mm; inner diame-
ter, 5 m]; Supelco, Bellefonte, PA) by using a
ﬂuorescence detection method. Brieﬂy, a high-perfor-
mance liquid chromatography pump was used to de-
liver a mobile phase of 50 mM potassium dihydrogen
phosphate (pH 4.6) and acetonitrile (87:13, vol/vol)
isocratically at 1.0 mL/min. Fluorescence detector RF
10AXL (Shimadzu Scientiﬁc Instruments, Columbia,
MD) was used to quantitate HCQ concentrations in
the presence of the internal standard chloroquine, by
using excitation and emission wavelengths of 320 and
380 nm, respectively. Steady-state HCQ concentra-
tions were determined as the average of plasma HCQ
concentrations obtained before cessation of therapy
(day 100). The plasma half-life was determined in 5
patients for whom adequate HCQ samples were avail-
able (2 data points beyond posttransplantation day
100). Interpatient variability, expressed as the coef-
ﬁcient of variability (CV) for HCQ steady-state con-
centrations, was calculated in all patients, whereas
intrapatient variability was performed in patients who
had at least 3 HCQ samples for analysis within the
ﬁrst 100 days after transplantation.
Immune Reconstitution
Lymphocyte subsets were analyzed on peripheral
blood samples obtained immediately before (day 21)
and 7 days after the initiation of HCQ (day 14) and
on posttransplantation days 30 and 100. Subset
analysis was performed by 2- and 3-color (ﬂuorescein
isothiocyanate, phycoerythrin, peridinin chlorophyll
protein) ﬂow cytometric immunophenotyping by us-
ing monoclonal antibodies directly conjugated to ﬂuo-
rochromes against CD3, CD4, CD8, CD19,
and CD16/56. Absolute counts were calculated for
each lymphocyte subset as the product of the absolute
white blood cell count and lymphocyte differential
percentage (by using a Coulter STKS Automated
Hematology Analyzer; Miami, FL), and the cellular
subset percentage (by using a Coulter Elite ﬂow cy-
tometer) [19]. On completion of the phase II trial,
blood samples were also obtained prospectively on day
30 and 100 from 36 URD recipients receiving
identical conditioning and GVHD prophylaxis, with the
exception of HCQ, for lymphocyte subset analysis.
IBMTR Controls
At the completion of the phase II study, the out-
comes of HCQ patients (acute GVHD and day 100
mortality) were compared with the outcomes of
matched controls who received a non–T cell–depleted
URD bone marrow transplant and reported to the
IBMTR database. The IBMTR is a voluntary study
group of 300 transplant centers worldwide that con-
tributes detailed information to a statistical center at
the Medical College of Wisconsin. Participants are
required to report all consecutive transplants. The
IBMTR database includes 40% to 45% of allogeneic
recipients since 1970. Computerized error checks,
physician review of submitted data, and on-site audits
of participating centers ensure data quality. Controls
were selected in the following manner. First, 376
potential controls were identiﬁed in the IBMTR da-
tabase by using the following criteria: adult (aged
17-60 years) recipients of HLA-identical URD trans-
plants for acute myeloid leukemia, acute lymphoid
leukemia, chronic myeloid leukemia (CML), myelo-
dysplastic syndrome, non-Hodgkin lymphoma, or se-
vere aplastic anemia performed between 1997 and
1999 with TBI and cyclophosphamide with or without
other drugs for pretransplantation conditioning and
with posttransplantation CSA and MTX with or with-
out other drugs for GVHD prophylaxis. Among those
376 patients, 102 controls were selected for each
HLA-identical transplant case by matching for diag-
nosis, pretransplantation disease status, and donor/
recipient sex match (female to male versus other).
Additionally, once matched for each of these variables,
the ﬁnal matched controls were selected on the basis
of the smallest age difference between case and con-
trols. There were insufﬁcient numbers of matched
controls available for HLA-mismatched transplant
cases, so these comparisons were restricted to 6 of 6
HLA-matched transplant recipients.
Statistical Considerations
The phase II trial was initially designed to detect a
25% reduction of grade II to IV acute GVHD in
patients treated with HCQ compared with historical
controls. Descriptive statistics were used to character-
ize patients receiving HCQ. In the comparison with
matched controls, stratiﬁed conditional logistic re-
gression and stratiﬁed Cox proportional hazards re-
gression were used to compare the 100-day mortality
and acute GVHD rates, respectively. The proportion-
ality assumption of the Cox model was tested by add-
ing a time-dependent covariate. The odds ratio of day
100 mortality and the relative risk of developing
H. Khoury et al.
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acute GVHD for case versus control patients were
estimated on the basis of the conditional logistic and
Cox models, respectively. The Kaplan-Meier estima-
tor was used to compute survival probabilities; cumu-
lative incidence was used to calculate probabilities of
developing acute GVHD. All analyses were per-
formed on a UNIX (Sun Solaris; Sun Microsystems
Inc, Palo Alto, CA) platform with SAS version 8.1
(SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Characteristics of study patients are summarized
in Table 1. Patients received transplants for acute
myeloid leukemia (n  22), acute lymphoid leukemia
(n  7), CML (n  12), myelodysplastic syndrome
(n  6), non-Hodgkin lymphoma (n  2), or severe
aplastic anemia (n  2). The median age was 40 years
(range, 17-58 years), 9 patients were mismatched at
either the class I (HLA-A, n  3; HLA-B, n  3) or
class II (HLA-DRB1, n  3) loci, and 7 male recipi-
ents (14%) received a graft from a female donor.
Patients were also classiﬁed for matching purposes
into early-, intermediate-, and advanced-disease
groups. The pretransplantation disease status for pa-
tients with leukemia was deﬁned as early for patients
in ﬁrst complete remission (n  10) or chronic phase
CML (n  7), intermediate for patients in second
complete remission or beyond (n 11) or accelerated-
phase CML (n  2), and advanced for relapsed leu-
kemia (n  8) or blast-phase CML (n  3). For
nonleukemic patients, early disease referred to refrac-
tory anemia (n 4) and severe aplastic anemia (n 2),
whereas advanced disease referred to patients with
refractory anemia with excess blasts or in transforma-
tion (n  2) and relapsed non-Hodgkin lymphoma
(n  2).
HCQ Toxicity
HCQ was well tolerated, and no cases of retinal
toxicity were observed. Neuropathy, myopathy, or
gastrointestinal toxicities attributable to HCQ were
not observed. One patient (2%) developed an allergic
skin rash 4 days after enrollment, and it was reversible
when HCQ was permanently discontinued.
Engraftment
Median times to neutrophil and platelet engraft-
ment were 13 days (range, 11-21 days) and 21 days
(range, 15-35 days), respectively. Three patients had
primary graft failure (6%), and therefore only 48 pa-
tients were included in the chimerism analyses.
Donor cell engraftment analysis performed on day
30 and day 100 showed 100% donor cells in 36
(98%) of 37 evaluable patients (50% in 1 patient) and
100% donor cells in 23 (80%) of 29 evaluable patients
(75% in 6 patients, all with relapsed disease), respec-
tively. Chimerism analyses were not performed in 11
and 19 patients on days 30 and 100, respectively,
because of death (n  11), imminent death (n  8), or
bone marrow test not done (n  11).
Immune Reconstitution
The effects of HCQ on lymphocyte subsets were
analyzed before and after transplantation. The addi-
tion of HCQ for 7 days had no effect on either the
total lymphocyte counts or the lymphocyte subsets
independently of the transplantation (day 14 com-
pared with day 21; data not shown). As shown in
Table 2, HCQ had no effect on lymphocyte subsets
on days 30 and 100 after transplantation, and
lymphocyte recovery was comparable to an institu-
tional nonmatched cohort of URD recipients receiv-
ing identical conditioning and GVHD prophylaxis,
with the exception of HCQ.
Pharmacokinetics
HCQ concentrations were linear within the con-
centration range of 50 to 1000 ng/mL. The lower
limit of quantitation for this assay was 30 ng/mL.
Interassay variability was 5.5%, 6.7%, and 5.4% for
75, 400, and 800 ng/mL, respectively. Intra-assay vari-
ability was 5% across the linear range of the cali-
bration curve. A total of 31 patients were evaluable for
HCQ steady-state levels. The overall median steady-
state HCQ concentration was 413 ng/mL, and inter-
patient variability was large (CV, 64%), ranging from
Table 1. Patient Characteristics
Variable
Study Cohort
(n  51)
Age, y, median (range) 40 (17-58)
<30 y, n (%) 14 (27%)
30–39 y, n (%) 11 (22%)
40–49 y, n (%) 18 (35%)
>50 y, n (%) 8 (16%)
Diagnosis
AML 22
ALL 7
CML 12
MDS 6
NHL 2
SAA 2
HLA matching
6/6 42 (82%)
HLA-A mm 3
HLA-B mm 3
HLA-DRB1 mm 3
F donor/M recipient 7 (14%)
AML indicates acute myeloid leukemia; ALL, acute lymphoid leu-
kemia; CML, chronic myeloid leukemia; MDS, myelodysplastic
syndrome; NHL, non-Hodgkin lymphoma; SAA, severe aplastic
anemia; mm, mismatched; F, female; M, male.
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0 to 1151 ng/mL within the ﬁrst 100 days after trans-
plantation. Within the same patient, HCQ steady-
state concentrations also demonstrated signiﬁcant
ﬂuctuation, with a median intrapatient CV of 53%
(range, 10%-86%). However, no consistent trend in
HCQ concentration was observed among the re-
peated measurements obtained during the ﬁrst 100
days of therapy (data not shown). The median termi-
nal half-life for HCQ in these URD marrow trans-
plant recipients was 10 days (range, 5.2-13.9 days).
HCQ steady-state concentrations were not statisti-
cally different in patients who experienced no GVHD
(median, 484 ng/mL; range, 221-1151 ng/mL), grade
I/II GVHD (median, 313 ng/mL; range, 0-981 ng/
mL), or grade III/IV acute GVHD (median, 333 ng/
mL; range, 48-672 ng/mL; P  .35; Figure 1). We
found no correlation between patients’ body weight
and HCQ serum concentrations.
Acute GVHD
Forty-eight patients engrafted and were evaluable
for acute GVHD. Acute GVHD was not observed in
21 patients (44%). Grades I and II were observed in 19
patients (39%), and grades III and IV acute GVHD
were observed in 8 patients (17%). Nineteen patients
(39%) had acute GVHD limited to the skin, and 8
(17%) had visceral involvement. Table 3 summarizes
organ involvement by acute GVHD. Acute GVHD
was refractory to corticosteroids in 6 patients and
contributed to their demise. Among 32 patients who
lived longer than 6 months and were therefore evalu-
able for chronic GVHD, 21 (62%) had chronic exten-
sive GVHD that required systemic immunosuppres-
sive therapy.
Survival
With a median follow-up of 50 months (range,
42-60 months), 15 patients are alive, and 36 (70%)
have died. A Kaplan-Meier survival curve for URD
recipients receiving HCQ is shown in Figure 2. Four-
teen patients had recurrent malignancy after trans-
plantation, and overall, 22 patients died from causes
other than relapse, including infections or GVHD and
multiorgan failure.
Comparison between Study Patients and IBMTR
Case-Matched Controls
Few HLA-mismatched transplant controls were
found in the IBMTR database, so this analysis was
limited to HLA-matched URD bone marrow trans-
plants. Forty-two recipients enrolled on the HCQ
study who engrafted were matched to 83 controls
chosen among 376 patients selected from the IBMTR
database by using the selection criteria described pre-
viously. The IBMTR database identiﬁed 2 controls for
all except 1 case, and age matching within 5 years was
Table 2. Peripheral Blood Lymphocyte Subsets Measured on Days 30 and 100 after URD Transplantation*
Lymphocyte
Subset
Peripheral Blood Levels (105/mL, mean (SD)
Day 30
(on HCQ)
(n  42)
Day  30
(n  36)
P Value
(No HCQ)
Day  100
(on HCQ)
(n  27)
Day  100
(n  22)
P Value
(No HCQ)
CD3 2.1 (2.8) 1.58 (1.46) .82 3.97 (4.8) 23 (9.4) .59
CD4 0.89 (1.1) 0.69 (0.68) .85 1.61 (2.9) 56 (2.1) .93
CD8 1.12 (1.9) 0.84 (1.1) .62 2.29 (2.7) 4.48 (7.2) .5
CD19 0.03 (0.06) 0.01 (0.03) .91 0.04 (0.1) 0.01 (0.03) .86
CD16/56 1.2 (0.9) 0.82 (0.75) .93 2.11 (1.8) 2.8 (6.3) .8
*Results in HCQ patients we are compared with those a cohort of URD recipients receiving identical conditioning and GVHD prophylaxis
except for HCQ.
Figure 1. Correlation between HCQ serum levels and development
of various grades of acute GVHD (aGVHD). There was no differ-
ence in HCQ levels that would predict severe (grades III and IV)
acute GVHD (Kruskal-Wallis test; P  .35)
Table 3. Staging and Grading of Acute GVHD (n  48)
Stage
Organ, n (%)
Skin Gut Liver
1/2 22 (46%) 2 (4%) 0
3 5 (10%) 2 (4%) 4 (8%)
4 0 4 (8%) 1 (2%)
Grade 0 I-II III IV
21 (44%) 19 (39%) 4 (8%) 4 (8%)
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feasible in 67 (81%) controls. Potential age effects
were examined by using continuous and dichotomous
variables (40 versus 40 years), but age had no
association with acute GVHD or 100-day mortality.
No signiﬁcant differences in the overall (grades II-IV)
incidence of acute GVHD were noted between HCQ-
treated patients and IBMTR controls, but there was a
non–statistically signiﬁcant trend for a lower inci-
dence of grade III and IV GVHD with HCQ. The
relative risks of developing grade II to IV and grade III
and IV acute GVHD for cases versus controls were
0.86 (95% conﬁdence interval, 0.47-1.60; P .64) and
0.44 (95% conﬁdence interval, 0.14-1.35; P  .15),
respectively. The probabilities of 100-day mortality
were 19% (8 of 42) and 39% (32 of 83) in cases and
controls, respectively. Table 4 summarizes causes of
death before day 100 in URD transplant recipients
receiving HCQ (n  8) and in controls (n  32).
Infection/GVHD was the primary cause of death in
both groups. Death from organ failure or interstitial
pneumonitis was not observed in HCQ patients but
occurred in 10 controls. Day 100 GVHD-free sur-
vival is presented in Figure 3; a signiﬁcantly lower
GVHD-related mortality was observed in HCQ-
treated patients (Figure 3B; P  .01).
DISCUSSION
CSA combined with short-course MTX with or
without corticosteroids is the most common GVHD
prophylactic regimen after URD transplantation and
is effective in preventing acute GVHD in 40% to 60%
of patients and life-threatening acute GVHD (grades
III and IV) in only 60% to 80% of patients [2-4,20].
These statistics highlight the need to investigate new
prophylactic immunosuppressive agents. Advances in
understanding the pathogenesis of GVHD have clar-
iﬁed the central role played by recipient antigen-pre-
senting cells (APC) in the development of GVHD
[21,22]. Recipient APC are required for the develop-
ment of CD8 T cell–dependent GVHD [21], and
cytokine production resulting from the CD4 T-cell/
APC interaction is essential for the recruitment of
effector cells involved in GVHD. These observations
have paved the way for novel therapeutic approaches
aiming to control GVHD by targeting APC.
HCQ is a lysosomotropic amine that blocks major
histocompatibility class II antigen processing and pre-
sentation through changes in lysosomal pH [6-11]. By
affecting late lysosomal acidiﬁcation, HCQ decreases
invariant chain dissociation from the class II molecule,
preventing antigen binding. HCQ also interferes di-
rectly with T-cell function at higher concentrations
(25 M) and inhibits CD3-dependent T-cell prolif-
eration. Extensive in vitro data have shown that HCQ
Figure 2. Kaplan-Meier survival estimate for all URD recipients
enrolled on the HCQ prophylactic trial (n  52).
Table 4. Causes of Death by Day 100 in URD Recipients Treated
with HCO (Case; n  42) and IBMTR Controls (n  83)
Cause of Death Case (%) Control (%)
Primary disease 1 (12) 4 (12)
Infection 5 (63) 8 (25)
GVHD 2 (25) 5 (16)
Interstitial pneumonitis 0 4 (12)
Organ failure 0 6 (19)
Other causes 0 5 (16)
Figure 3. Overall acute GVHD and grade III and IV acute GVHD
(AGVHD)–free survival for forty-two 6-antigen–matched URD
recipients enrolled on the HCQ prophylactic trial and IBMTR
controls.
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reduces T-cell proliferation in response to multiple
stimuli, including allogeneic targets, through inhibi-
tion of minor histocompatibility antigen–mediated T-
cell activation. HCQ also inhibits interleukin-1 and
interleukin-6 production in a dose-dependent fashion
after mitogen stimulation of T lymphocytes and
monocytes. It is important to note that HCQ acts
synergistically with the immunosuppressive activity of
CSA, making HCQ a particularly attractive agent for
the prevention and treatment of GVHD [8]. The
anti-GVHD activity of HCQ has been demonstrated
both in mice and in humans. This study is the ﬁrst
clinical trial to evaluate HCQ administered for
GVHD prophylaxis after allogeneic hematopoietic
stem cell transplantation.
In this study, HCQ was administered orally at the
daily dose of 800 mg. This dose was derived from
pharmacokinetic studies performed in both volunteers
[23] and patients with rheumatoid arthritis [24]. In
healthy volunteers, HCQ blood levels of 434 to 2170
ng/mL were achievable after administration of 400
mg/d. In rheumatoid arthritis patients, administration
of HCQ (400 mg/d) resulted in steady-state blood
concentrations of 371 to 1574 ng/mL [23-25]. In
URD recipients, HCQ was relatively well absorbed;
however, despite administration of a high dose of
HCQ (800 mg/d), blood levels were comparable to
those of healthy volunteers or rheumatoid patients
receiving 400 mg/d. Drug interactions, kinetics of
absorption and/or elimination after transplantation,
and compliance may account for these ﬁndings. Sim-
ilar to healthy volunteer and rheumatoid arthritis pa-
tients, intra- and interpatient variability was wide
(blood levels varied from 0 to 2.7 M). Importantly
for an orally administered agent, absorption did not
seem to be a limiting factor because no differences in
HCQ steady-state concentrations were observed
among patients who did and did not develop acute
GVHD (Figure 1); however, the number of patients
with severe acute GVHD was small. HCQ was initi-
ated 21 days before transplantation to perform phar-
macologic analyses and to evaluate the effects of HCQ
on lymphocytes independently from transplantation.
Additionally, murine models developed by Schultz et
al. [10] have suggested that greater immunosuppres-
sive effects occur when HCQ is initiated at least 5 days
before transplantation.
The addition of HCQ to CSA, MTX, and corti-
costeroids was extremely well tolerated and was not
associated with side effects. Speciﬁcally, retinal toxic-
ity was not observed. Delays in engraftment did not
occur, and there were no increases in the incidence of
graft failure or unexpected posttransplantation acute
complications. Administration of HCQ had no effect
on absolute lymphocyte counts or lymphocyte subsets
independently from transplantation. When compared
with a nonmatched cohort of URD recipients receiv-
ing the same conditioning and GVHD prophylaxis
except for HCQ, the addition of HCQ did not seem
to affect posttransplantation lymphocyte recovery ei-
ther.
The low incidence of acute GVHD observed after
URD transplantation in this relatively older cohort of
patients (50% older than 40 years) is very encourag-
ing. Indeed, 44% of patients did not develop acute
GVHD, and severe acute GVHD occurred in only
17%. These results compare favorably with published
reports of acute GVHD in URD recipients [2-4,26-
30]. However, in the absence of randomized trial, it is
possible that other factors, such as patient selection or
conditioning regimen, might have inﬂuenced out-
comes. Therefore, in collaboration with the IBMTR,
we identiﬁed matched controls to validate the results
of this phase II trial. Cumulative incidences of acute
GVHD were not different between cases and controls
(relative risk, 0.86; 95% conﬁdence interval, 0.47-1.6);
nevertheless, a trend for a lower incidence of severe
GVHD was observed with HCQ that translated into a
signiﬁcantly better GVHD-free survival (P  .01).
In summary, our study demonstrates that HCQ
can be safely administered after URD transplantation
and is associated with reduced severe acute GVHD-
related mortality when added to CSA, MTX, and
prednisone. An ongoing randomized placebo-con-
trolled phase III trial will clarify the role of HCQ
added to single-agent CSA in the prevention of acute
and chronic GVHD after HLA-matched related do-
nor allogeneic peripheral blood stem cell transplanta-
tion.
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